A detailed history of Vanguard Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,994,459 shares of RVNC stock, worth $15.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,994,459
Previous 5,398,406 11.04%
Holding current value
$15.4 Million
Previous $26.6 Million 42.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.34 - $4.73 $1.39 Million - $2.82 Million
596,053 Added 11.04%
5,994,459 $15.4 Million
Q1 2024

May 10, 2024

BUY
$4.65 - $9.31 $1.53 Million - $3.06 Million
328,781 Added 6.49%
5,398,406 $26.6 Million
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $1.62 Million - $3.12 Million
278,166 Added 5.81%
5,069,625 $44.6 Million
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $1.59 Million - $3.48 Million
138,683 Added 2.98%
4,791,459 $55 Million
Q2 2023

Aug 14, 2023

BUY
$24.7 - $37.61 $1.31 Million - $1.99 Million
53,031 Added 1.15%
4,652,776 $118 Million
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $1.9 Million - $3.65 Million
103,429 Added 2.3%
4,599,745 $148 Million
Q4 2022

Feb 10, 2023

BUY
$18.32 - $30.66 $3.36 Million - $5.62 Million
183,420 Added 4.25%
4,496,316 $83 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $8.74 Million - $17.4 Million
609,841 Added 16.47%
4,312,896 $116 Million
Q2 2022

Aug 12, 2022

BUY
$11.52 - $20.4 $665,210 - $1.18 Million
57,744 Added 1.58%
3,703,055 $51.2 Million
Q1 2022

May 13, 2022

BUY
$12.36 - $20.31 $531,653 - $873,614
43,014 Added 1.19%
3,645,311 $71.1 Million
Q4 2021

Feb 14, 2022

BUY
$12.46 - $27.87 $216,704 - $484,715
17,392 Added 0.49%
3,602,297 $58.8 Million
Q3 2021

Nov 12, 2021

SELL
$25.78 - $33.21 $717,792 - $924,666
-27,843 Reduced 0.77%
3,584,905 $99.9 Million
Q2 2021

Aug 13, 2021

BUY
$26.8 - $31.84 $96.8 Million - $115 Million
3,612,748 New
3,612,748 $107 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.